S M Rowe

Summary

Affiliation: University of Alabama at Birmingham
Country: USA

Publications

  1. doi request reprint Acquired defects in CFTR-dependent β-adrenergic sweat secretion in chronic obstructive pulmonary disease
    Clifford A Courville
    Department of Medicine, MCLM 706, 1918 University Blvd, University of Alabama at Birmingham, Birmingham, AL, USA
    Respir Res 15:25. 2014
  2. doi request reprint Impact of heterozygote CFTR mutations in COPD patients with chronic bronchitis
    S Vamsee Raju
    Department of Medicine, University of Alabama at Birmingham, MCLM 706 1918 University Blvd, Birmingham, AL, USA
    Respir Res 15:18. 2014
  3. pmc Reduced sodium transport with nasal administration of the prostasin inhibitor camostat in subjects with cystic fibrosis
    Steven M Rowe
    Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294 0006, USA
    Chest 144:200-7. 2013
  4. pmc Progress in cystic fibrosis and the CF Therapeutics Development Network
    Steven M Rowe
    Department of Medicine, University of Alabama at Birmingham, 1819 University Boulevard MCLM 768, Birmingham, AL 35294, USA
    Thorax 67:882-90. 2012
  5. pmc Restoration of W1282X CFTR activity by enhanced expression
    Steven M Rowe
    Department of Medicine, Gregory Fleming James Cystic Fibrosis Research Center, University of Alabama at Birmingham, Birmingham, Alabama 35294 0006, USA
    Am J Respir Cell Mol Biol 37:347-56. 2007
  6. pmc Detection of cystic fibrosis transmembrane conductance regulator activity in early-phase clinical trials
    Steven M Rowe
    Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama 35294 0006, USA
    Proc Am Thorac Soc 4:387-98. 2007
  7. pmc Nasal potential difference measurements to assess CFTR ion channel activity
    Steven M Rowe
    Department of Medicine, University of Alabama, Birmingham, AL 35294 0006, USA
    Methods Mol Biol 741:69-86. 2011
  8. ncbi request reprint Advances in cystic fibrosis therapies
    Steven M Rowe
    Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA
    Curr Opin Pediatr 18:604-13. 2006
  9. pmc Potential role of high-mobility group box 1 in cystic fibrosis airway disease
    Steven M Rowe
    Department University of Alabama at Birmingham, Birmingham, AL 35294 0006, USA
    Am J Respir Crit Care Med 178:822-31. 2008
  10. pmc DeltaF508 CFTR processing correction and activity in polarized airway and non-airway cell monolayers
    S M Rowe
    Department of Medicine, University of Alabama at Birmingham, 1530 3rd Ave South, Birmingham, AL 35294 0005, United States
    Pulm Pharmacol Ther 23:268-78. 2010

Collaborators

Detail Information

Publications22

  1. doi request reprint Acquired defects in CFTR-dependent β-adrenergic sweat secretion in chronic obstructive pulmonary disease
    Clifford A Courville
    Department of Medicine, MCLM 706, 1918 University Blvd, University of Alabama at Birmingham, Birmingham, AL, USA
    Respir Res 15:25. 2014
    ..Recently, sweat evaporimetry has been shown to efficiently measure β-adrenergic sweat rate and specifically quantify CFTR function in the secretory coil of the sweat gland...
  2. doi request reprint Impact of heterozygote CFTR mutations in COPD patients with chronic bronchitis
    S Vamsee Raju
    Department of Medicine, University of Alabama at Birmingham, MCLM 706 1918 University Blvd, Birmingham, AL, USA
    Respir Res 15:18. 2014
    ..Consequently, COPD patients with chronic bronchitis may have a higher rate of CFTR mutations compared to the general population...
  3. pmc Reduced sodium transport with nasal administration of the prostasin inhibitor camostat in subjects with cystic fibrosis
    Steven M Rowe
    Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294 0006, USA
    Chest 144:200-7. 2013
    ..Its direct inhibition by camostat represents a potential approach to inhibiting sodium transport in cystic fibrosis (CF)...
  4. pmc Progress in cystic fibrosis and the CF Therapeutics Development Network
    Steven M Rowe
    Department of Medicine, University of Alabama at Birmingham, 1819 University Boulevard MCLM 768, Birmingham, AL 35294, USA
    Thorax 67:882-90. 2012
    ..Efforts to advance CF biomarkers, necessary to accelerate the therapeutic goals of the network, are also summarised...
  5. pmc Restoration of W1282X CFTR activity by enhanced expression
    Steven M Rowe
    Department of Medicine, Gregory Fleming James Cystic Fibrosis Research Center, University of Alabama at Birmingham, Birmingham, Alabama 35294 0006, USA
    Am J Respir Cell Mol Biol 37:347-56. 2007
    ..These findings provide evidence that W1282X CFTR exhibits membrane localization and retained chloride channel function after enhanced expression, and suggest that patients harboring this mutation may be more susceptible to CFTR rescue...
  6. pmc Detection of cystic fibrosis transmembrane conductance regulator activity in early-phase clinical trials
    Steven M Rowe
    Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama 35294 0006, USA
    Proc Am Thorac Soc 4:387-98. 2007
    ..Recommendations are presented to advance our understanding of these biomarkers and to improve their capacity to predict cystic fibrosis outcomes...
  7. pmc Nasal potential difference measurements to assess CFTR ion channel activity
    Steven M Rowe
    Department of Medicine, University of Alabama, Birmingham, AL 35294 0006, USA
    Methods Mol Biol 741:69-86. 2011
    ..This chapter will elaborate on the electrophysiological principles behind the test, the equipment required, the methods, and the analysis of the data...
  8. ncbi request reprint Advances in cystic fibrosis therapies
    Steven M Rowe
    Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA
    Curr Opin Pediatr 18:604-13. 2006
    ..This review describes recent developments in cystic fibrosis pulmonary therapies intended to treat various facets of the disease, including several treatments currently in development...
  9. pmc Potential role of high-mobility group box 1 in cystic fibrosis airway disease
    Steven M Rowe
    Department University of Alabama at Birmingham, Birmingham, AL 35294 0006, USA
    Am J Respir Crit Care Med 178:822-31. 2008
    ..High-mobility group box 1 (HMGB1) is a potent inflammatory mediator elevated in sepsis and rheumatoid arthritis, although its role in cystic fibrosis (CF) lung disease is unknown...
  10. pmc DeltaF508 CFTR processing correction and activity in polarized airway and non-airway cell monolayers
    S M Rowe
    Department of Medicine, University of Alabama at Birmingham, 1530 3rd Ave South, Birmingham, AL 35294 0005, United States
    Pulm Pharmacol Ther 23:268-78. 2010
    ..The results identify important differences in DeltaF508 CFTR activation in polarizing epithelial models of CF, and have important implications regarding detection of rescued of DeltaF508 CFTR in vivo...
  11. pmc Suppression of CFTR premature termination codons and rescue of CFTR protein and function by the synthetic aminoglycoside NB54
    Steven M Rowe
    Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA
    J Mol Med (Berl) 89:1149-61. 2011
    ....
  12. pmc A critical role for LTA4H in limiting chronic pulmonary neutrophilic inflammation
    Robert J Snelgrove
    Division of Pulmonary, Allergy and Critical Care Medicine, University of Alabama at Birmingham Lung Health Center, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA
    Science 330:90-4. 2010
    ..These studies imply that therapeutic strategies inhibiting LTA(4)H to prevent LTB(4) generation may not reduce neutrophil recruitment because of elevated levels of PGP...
  13. ncbi request reprint A novel proteolytic cascade generates an extracellular matrix-derived chemoattractant in chronic neutrophilic inflammation
    Amit Gaggar
    Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA
    J Immunol 180:5662-9. 2008
    ..These experiments highlight unique protease interactions with structural proteins regulating innate immunity and support a role for these peptides as novel biomarkers and therapeutic targets for chronic, neutrophilic lung diseases...
  14. pmc No detectable improvements in cystic fibrosis transmembrane conductance regulator by nasal aminoglycosides in patients with cystic fibrosis with stop mutations
    John P Clancy
    Department of Pediatrics, University of Alabama at Birmingham, 1600 7th Avenue South, Birmingham, AL 35233, USA
    Am J Respir Cell Mol Biol 37:57-66. 2007
    ..The study provides valuable information on parameters of the nasal potential difference measurements for use in future multicenter clinical trials...
  15. pmc Activation of the cystic fibrosis transmembrane conductance regulator by the flavonoid quercetin: potential use as a biomarker of ΔF508 cystic fibrosis transmembrane conductance regulator rescue
    Louise C Pyle
    Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA
    Am J Respir Cell Mol Biol 43:607-16. 2010
    ..Quercetin activates CFTR-mediated anion transport in respiratory epithelia in vitro and in vivo, and may be useful in studies intended to detect the rescue of ΔF508 CFTR by nasal potential difference...
  16. pmc An international randomized multicenter comparison of nasal potential difference techniques
    George M Solomon
    University of Alabama at Birmingham, Birmingham, AL 35294 0006, USA
    Chest 138:919-28. 2010
    ..Unreliability, excessive artifacts, and lack of standardization of current testing systems can compromise its use as a diagnostic test and outcome measure for clinical trials...
  17. ncbi request reprint Cystic fibrosis
    Steven M Rowe
    Gregory Fleming James Cystic Fibrosis Research Center, University of Alabama at Birmingham, Birmingham, AL 35294, USA
    N Engl J Med 352:1992-2001. 2005
  18. doi request reprint Pharmaceuticals targeting nonsense mutations in genetic diseases: progress in development
    Steven M Rowe
    Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35233, USA
    BioDrugs 23:165-74. 2009
    ..These results, coupled with our improved understanding of how translation termination is regulated at PTCs, will help guide future directions of research involving this innovative treatment strategy for genetic diseases...
  19. pmc Bioelectric effects of quinine on polarized airway epithelial cells
    Eleanor Bates
    Gregory Fleming James Cystic Fibrosis Research Center, University of Alabama at Birmingham, 1900 University Boulevard, Birmingham, AL 35294, USA
    J Cyst Fibros 6:351-9. 2007
    ..The use of quinine as a taste-masking agent may have bioelectric effects relevant to CF trials using aerosolized drug delivery...
  20. pmc Association of cystic fibrosis genetic modifiers with congenital bilateral absence of the vas deferens
    Viktoria Havasi
    Department of Medicine and Gregory Fleming James Cystic Fibrosis Research Center, University of Alabama at Birmingham, Birmingham, Alabama 35294, USA
    Fertil Steril 94:2122-7. 2010
    ..We tested the hypothesis that polymorphisms of transforming growth factor (TGF)-β1 (rs 1982073, rs 1800471) and endothelin receptor type A (EDNRA) (rs 5335, rs 1801708) are associated with the CBAVD phenotype...
  21. pmc Regulatory domain phosphorylation to distinguish the mechanistic basis underlying acute CFTR modulators
    Louise C Pyle
    Departments of Genetics, University of Alabama at Birmingham, 35294 0006, USA
    Am J Physiol Lung Cell Mol Physiol 301:L587-97. 2011
    ..g., activators and potentiators), and demonstrates that a number of different mechanisms can be successfully employed to activate mutant CFTR...
  22. doi request reprint Genetic and reproductive knowledge among adolescents and adults with cystic fibrosis
    Grace H Houser
    Chest 133:1533. 2008